Amidst the ongoing debate on the use of DEL-1, its capacity to suppress inflammation and cytotoxicity should be acknowledged as a therapeutic option for cardiovascular diseases, targeting multiple cell types including ECs and VSMCs (Wang et al., 2022b). The gene discussed is EDIL3; the disease is cardiovascular disorder.